There are also pharmaceutical companies "controlling sales" and being punished by antitrust

On July 22, the State Administration of Market Supervision reported that when Hainan Yishun Pharmaceuticals sold an exclusive product, it reached a monopoly agreement with the dealer to "limit the minimum resale price" to eliminate and restrict market competition, damage consumers to consumers Benefit.

The General Administration of Market Supervision disclosed that in August 2020, the monopoly reporting clues received by the Hainan Market Supervision and Administration Bureau immediately investigated Yishun Pharmaceutical. Yishun Pharmaceutical was established in 2003. The product involved is the exclusive drug Lianzhi anti -inflammatory drip pill, which is mainly used for clearing heat and detoxifying.

The survey results show that Yishun Pharmaceuticals signed contracts such as the "Price Management Agreement" with 40 dealers across the country, stipulating that the shipments and end prices of Lianzhi Diaoyan Pills of different specifications are agreed. To other areas, selling networks, low -cost sales.

Because the monopoly agreement was not implemented, and Yishun Pharmaceutical "cooperated with the investigation" to provide relevant evidence, the Hainan Municipal Supervision Bureau decided to impose a fine of 200,000 yuan on the Yishun Pharmaceutical Office. Within 15 days.

Yishun Pharmaceutical is engaged in a typical "control" behavior in the pharmaceutical industry. It was originally a common actions adopted by pharmaceutical companies to control the price of drugs and avoid the competition of dealers' malicious price cuts. But in the context of antitrust policies, "controlling sales" has become the target of currently being hit.

In recent years, the state has continuously increased antitrust efforts to the pharmaceutical industry. The "Annual Report of China's Anti-Monopoly Law Enforcement" shows that from 2019-2021, the state investigated a total of 102 medical industry monopoly cases, with a cumulative fine of 950 million yuan, involving well-known enterprises such as pilot pharmaceutical industry.

From August 1st this year, the new antitrust method will be officially implemented. The new law stipulates the illegal liability of the company that signed the monopoly agreement: to reach the monopoly agreement and the implementation, in addition to confiscating the illegal income, it will also be fined according to the sales of the previous year. Fine fines.

Writing | Guyue

Edit ｜ Jiang Yun Jia Ting

Operation | Valley

Illustration | Visual China

### Anti -monopoly ###

- END -